|
?:authorAffiliation
|
-
[\'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK.\', \'Late-stage development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.\', \'The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK.\', \'National Infection Service, Public Health England, Salisbury, UK.\', \'Late-stage development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Cytel Inc., Cambridge, MA, USA.\', \'Microbial Sciences, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA.\', \'Late-stage development Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.\', \'Chinese Academy of Medical Science (CAMS) Oxford Institute (COI), University of Oxford, Oxford, UK.\', \'NIHR Oxford Biomedical Centre, Oxford, UK.\', \'Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. merryn.voysey@paediatrics.ox.ac.uk.\', \'NIHR Oxford Biomedical Centre, Oxford, UK. merryn.voysey@paediatrics.ox.ac.uk.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}